.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,616,334

« Back to Dashboard

Summary for Patent: 5,616,334

Title: Low toxicity drug-lipid systems
Abstract:Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in about a 7:3 mole ratio. The lipid complexes contain a bioactive agent, and may be made by a number of procedures, at high drug:lipid ratios. These compositions of high drug:lipid complexes (HDLCs) may be administered to mammals such as humans for the treatment of infections, with substantially equivalent or greater efficacy and reduced drug toxicities as compared to the drugs in their free form. Also disclosed is a novel liposome-loading procedure, which may also be used in the formation of the HDLCs.
Inventor(s): Janoff; Andrew S. (Yardley, PA), Boni; Lawrence (Monmouth Junction, NJ), Madden; Thomas D. (Vancouver, CA), Cullis; Pieter R. (Vancouver, CA), Lenk; Robert P. (Lambertville, NJ), Kearns; John J. (Princeton, NJ), Durning; Anthony G. (Yardley, PA), Klimchak; Robert (Flemington, NJ), Portnoff; Joel (Richboro, PA)
Assignee: The Liposome Company, Inc. (Princeton, NJ)
Application Number:08/430,699
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;
Patent PDF download available with subscription

No matches for this query

International Patent Family for Patent: 5,616,334

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria113468<disabled in preview>
Austria118169<disabled in preview>
Australia1799088<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc